• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CD30+ 皮肤 T 细胞淋巴瘤的 QuPath 分析。

QuPath Analysis for CD30+ Cutaneous T-Cell Lymphoma.

机构信息

University Clinic for Dermatology, Johannes Wesling Medical Centre, Minden, Germany.

University Hospital of Ruhr-University, Bochum, Germany.

出版信息

Am J Dermatopathol. 2023 Feb 1;45(2):93-98. doi: 10.1097/DAD.0000000000002330.

DOI:10.1097/DAD.0000000000002330
PMID:36669072
Abstract

BACKGROUND

Mycosis fungoides is the most common subtype of cutaneous T-cell lymphoma, in which the expression of cluster of differentiation 30 (CD30)+ subtype can now be treated with the CD30 antibody conjugate brentuximab vedotin. Diagnostic methods are based on immunohistochemical (IHC) staining followed by manual assessment by pathologists, which is always a subjective calculation. QuPath, an open-source software for digital pathology image analysis, satisfies the requirements of objective approaches.

METHODS

Ten samples from mycosis fungoides patients with CD30 expression at different stages were stained for CD3 and CD30 by IHC staining, scanned, and quantitative analysis was performed using QuPath (version 2.1). Each slide was independently assessed by 3 board-certified dermatopathologists.

RESULTS

Individual estimates for CD30+/CD3+ cells varied among the individual histopathologists (mean coefficient of variation, 0.46; range, 0-0.78). QuPath analysis showed excellent separation between the positively stained cells for CD3 and CD30 IHC and other cells and tissue structures, although the results correlated strongly with the respective mean estimates of the 3 histopathologists (Pearson-R 0.93).

CONCLUSIONS

The results show a high interobserver variability evaluation of IHC markers, although quantitative image analysis offer a significant advantage for comparison. This is not only relevant for clinical routine but also especially critical in therapeutic studies addressing targeted molecules.

摘要

背景

蕈样肉芽肿是皮肤 T 细胞淋巴瘤最常见的亚型,现在可以用 CD30 抗体偶联药物 Brentuximab vedotin 治疗表达 CD30+亚型的患者。诊断方法基于免疫组织化学(IHC)染色,然后由病理学家进行手动评估,这始终是一种主观计算。QuPath 是一种用于数字病理学图像分析的开源软件,满足客观方法的要求。

方法

10 例不同阶段蕈样肉芽肿患者的 CD30 表达样本进行 CD3 和 CD30 的 IHC 染色,扫描并使用 QuPath(版本 2.1)进行定量分析。每位病理学家均独立评估每张幻灯片。

结果

个别组织病理学家对 CD30+/CD3+细胞的个体估计值存在差异(平均变异系数为 0.46;范围为 0-0.78)。尽管 QuPath 分析显示 CD3 和 CD30 IHC 阳性染色细胞与其他细胞和组织结构之间有很好的分离,但与 3 位组织病理学家各自的平均估计值相关性很强(Pearson-R 0.93)。

结论

结果表明,IHC 标志物的观察者间变异性评估很高,尽管定量图像分析在比较方面具有显著优势。这不仅与临床常规相关,而且在针对靶向分子的治疗研究中尤其关键。

相似文献

1
QuPath Analysis for CD30+ Cutaneous T-Cell Lymphoma.CD30+ 皮肤 T 细胞淋巴瘤的 QuPath 分析。
Am J Dermatopathol. 2023 Feb 1;45(2):93-98. doi: 10.1097/DAD.0000000000002330.
2
Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.本妥昔单抗治疗经治的日本CD30阳性皮肤T细胞淋巴瘤患者的I/II期临床试验。
J Dermatol. 2024 Aug;51(8):1037-1049. doi: 10.1111/1346-8138.17324. Epub 2024 Jun 14.
3
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.对 Brentuximab vedotin 与医师选择的回应:根据 CD30 表达和大细胞转化状态在蕈样肉芽肿患者中的比较:ALCANZA 子分析。
Eur J Cancer. 2021 May;148:411-421. doi: 10.1016/j.ejca.2021.01.054. Epub 2021 Mar 29.
4
Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.在用维布妥昔单抗治疗的复发性皮肤CD30+淋巴样肿瘤中,通过免疫组织化学检测发现CD30表达存在可变缺失。
J Cutan Pathol. 2019 Nov;46(11):823-829. doi: 10.1111/cup.13545. Epub 2019 Aug 2.
5
Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.CD30 阴性、治疗抵抗的蕈样肉芽肿对 Brentuximab vedotin 治疗的显著反应。
Dermatol Ther. 2019 Mar;32(2):e12835. doi: 10.1111/dth.12835. Epub 2019 Feb 17.
6
Intraindividual variability of CD30 expression in mycosis fungoides -implications for diagnostic evaluation and therapy.蕈样肉芽肿中 CD30 表达的个体内变异性——对诊断评估和治疗的影响。
Histopathology. 2022 Jul;81(1):55-64. doi: 10.1111/his.14660. Epub 2022 May 4.
7
Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.本妥昔单抗治疗皮肤T细胞淋巴瘤:来自西班牙原发性皮肤淋巴瘤登记处的数据。
J Eur Acad Dermatol Venereol. 2023 Jan;37(1):57-64. doi: 10.1111/jdv.18563. Epub 2022 Sep 9.
8
Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.抗 CD30 抗体药物偶联物治疗淋巴瘤:现有知识、尚存争议和未来展望。
Ann Hematol. 2023 Jan;102(1):13-29. doi: 10.1007/s00277-022-05054-9. Epub 2022 Dec 13.
9
Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.本妥昔单抗维特辛治疗 CD30 阳性皮肤 T 细胞淋巴瘤:一种靶向治疗方法。
Future Oncol. 2017 Nov;13(27):2405-2411. doi: 10.2217/fon-2017-0263. Epub 2017 Aug 14.
10
A Case Series on the Use of Brentuximab Vedotin for the Treatment of Mycosis Fungoides.布仑妥昔单抗贝妥昔单抗治疗蕈样肉芽肿的病例系列研究
J Drugs Dermatol. 2023 Dec 1;22(12):e33-e34. doi: 10.36849/JDD.6981.

引用本文的文献

1
Enhanced diagnostic potential of CSPG4 in melanoma and nevi: a comparative study with PRAME, CDC7 and Ki67.CSPG4在黑色素瘤和痣中的诊断潜力增强:与PRAME、CDC7和Ki67的比较研究
J Pathol. 2025 Jul 23. doi: 10.1002/path.6450.
2
Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology.数字病理学在非小细胞肺癌肿瘤百分比估计中的一致性。
Sci Rep. 2024 Oct 15;14(1):24163. doi: 10.1038/s41598-024-75175-w.
3
Ultrastructural and immunohistochemical evaluation of hyperplastic soft tissues surrounding dental implants in fibular jaws.
腓骨下颌骨中种植体周围增生软组织的超微结构和免疫组织化学评估。
Sci Rep. 2024 May 10;14(1):10717. doi: 10.1038/s41598-024-60474-z.
4
Semantic modeling of cell damage prediction: a machine learning approach at human-level performance in dermatology.细胞损伤预测的语义建模:皮肤科达到人类水平性能的机器学习方法。
Sci Rep. 2023 May 23;13(1):8336. doi: 10.1038/s41598-023-35370-7.